Bimatoprost Patent Expiration
Bimatoprost is Used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first introduced by Abbvie Inc
Bimatoprost Patents
Given below is the list of patents protecting Bimatoprost, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zolymbus | US10314780 | Drippable Opthalmic Bimatoprost Gel | Jun 08, 2036 | Thea Pharma |
| Durysta | US9492316 | Prostamide-containing intraocular implants and methods of use thereof | Oct 31, 2034 | Abbvie |
| Durysta | US9980974 | Prostamide-containing intraocular implants and methods of use thereof | Oct 31, 2034 | Abbvie |
| Durysta | US8629185 | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof | Jul 15, 2031 | Abbvie |
| Durysta | US7799336 | Hypotensive lipid-containing biodegradable intraocular implants and related methods | Apr 24, 2029 | Abbvie |
| Lumigan | US7851504 | Enhanced bimatoprost ophthalmic solution | Jun 13, 2027 | Abbvie |
| Durysta | US8206737 | Hypotensive lipid-containing biodegradable intraocular implants and related methods | Apr 07, 2027 | Abbvie |
| Durysta | US10441543 | Processes for making cyclic lipid implants for intraocular use | Dec 19, 2026 | Abbvie |
| Durysta | US9149428 | Processes for making cyclic lipid implants for intraocular use | Dec 19, 2026 | Abbvie |
| Lumigan | US8278353 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US8299118 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US8309605 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US8338479 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US8524777 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US8586630 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US8772338 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US8933120 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US8933127 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US9155716 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Lumigan | US9241918 | Enhanced bimatoprost ophthalmic solution |
Mar 16, 2025
(Expired) | Abbvie |
| Durysta | US8673341 | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb 19, 2025
(Expired) | Abbvie |
| Latisse | US7351404 | Method of enhancing hair growth |
May 25, 2024
(Expired) | Abbvie |
| Latisse | US8101161 | Method of enhancing hair growth |
May 25, 2024
(Expired) | Abbvie |
| Durysta | US10398707 | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr 30, 2024
(Expired) | Abbvie |
| Latisse | US8038988 | Method of enhancing hair growth |
Aug 25, 2023
(Expired) | Abbvie |
| Latisse | US8263054 | Method of enhancing hair growth |
Aug 25, 2023
(Expired) | Abbvie |
| Latisse | US8632760 | Method of enhancing hair growth |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US8758733 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US8926953 | Method of enhancing hair growth |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US8986715 | Method of enhancing hair growth |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US9216183 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US9226931 | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan 15, 2023
(Expired) | Abbvie |
| Latisse | US7388029 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan 21, 2022
(Expired) | Abbvie |
| Latisse | US8541466 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan 31, 2021
(Expired) | Abbvie |
| Latisse | US8906962 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan 31, 2021
(Expired) | Abbvie |
| Latisse | US9579270 | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan 31, 2021
(Expired) | Abbvie |
| Durysta | US7033605 | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct 20, 2020
(Expired) | Abbvie |
| Lumigan | US5688819 | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug 19, 2014
(Expired) | Abbvie |
| Latisse | US8017655 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov 27, 2012
(Expired) | Abbvie |
| Lumigan | US8017655 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov 27, 2012
(Expired) | Abbvie |
| Latisse | US6403649 | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep 21, 2012
(Expired) | Abbvie |
| Lumigan | US6403649 | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep 21, 2012
(Expired) | Abbvie |
Bimatoprost's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Bimatoprost:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
